Antipsychotic Medication Prescribing Trends in Children and Adolescents

Overview

Journal J Pediatr Health Care

Specialties Health Services
Nursing
Pediatrics

Date 2012 Feb 25

PMID 22360933

Citations 47

Authors

Joyce Nolan Harrison

Fallon Cluxton-Keller

Deborah Gross

Affiliations

Soon will be listed here.

Abstract

The Food and Drug Administration has approved the use of antipsychotic medications in some children and adolescents with severe emotional and behavioral disorders. However, recent national data show a dramatic rise in off-label and Food and Drug Administration-approved uses of these medications. Of particular note is a twofold to fivefold increase in the use of antipsychotic medications in preschool children, despite little information on their long-term effects. This article describes the trend in pediatric antipsychotic medication use, possible explanations for the increase, implications for children's health, and recommendations for pediatric providers who work with parents of children and adolescents who seek or receive antipsychotic medication treatments.

Citing Articles

Modeling and scientific analysis of pediatric medication evaluation based on MDM-DEA-Malmquist model: construction of health management in pediatrics in developing countries.

Fang K, Xue S Ital J Pediatr. 2025; 51(1):29.

PMID: 39920819 PMC: 11806530. DOI: 10.1186/s13052-025-01893-0.

Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in China: a real-world study.

Zhaojian W, Meizhu J, Jun H, Shanshan G, Jiping H, Zhigang Z Child Adolesc Psychiatry Ment Health. 2024; 18(1):77.

PMID: 38907356 PMC: 11193198. DOI: 10.1186/s13034-024-00766-4.

Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population.

Pesiou S, Barcelo R, Papazisis G, Torres F, Pontes C Front Pharmacol. 2024; 15:1348887.

PMID: 38549664 PMC: 10972865. DOI: 10.3389/fphar.2024.1348887.

The Utah psychotropic oversight program: collaboratively addressing antipsychotic use within youth in foster care without prior authorization.

Monson E, Shastri S, Chen D, Madden S, Keeshin B Front Psychiatry. 2023; 14:1271165.

PMID: 38025462 PMC: 10654962. DOI: 10.3389/fpsyt.2023.1271165.

Comparison of inpatient psychiatric medication management in gender diverse youth with cisgender peers.

Carrillo N, McGurran M, Melton B, Moeller K Ment Health Clin. 2023; 13(4):169-175.

PMID: 37860590 PMC: 10583259. DOI: 10.9740/mhc.2023.08.169.

References

McMillen J, Zima B, Scott Jr L, Auslander W, Munson M, Ollie M . Prevalence of psychiatric disorders among older youths in the foster care system. J Am Acad Child Adolesc Psychiatry. 2004; 44(1):88-95. DOI: 10.1097/01.chi.0000145806.24274.d2. View

Zito J, Safer D, Valluri S, Gardner J, Korelitz J, Mattison D . Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol. 2007; 17(2):195-203. DOI: 10.1089/cap.2007.0006. View

Spaulding R, Belz N, DeLurgio S, Williams A . Cost savings of telemedicine utilization for child psychiatry in a rural Kansas community. Telemed J E Health. 2010; 16(8):867-71. DOI: 10.1089/tmj.2010.0054. View

Meadows T, Valleley R, Haack M, Thorson R, Evans J . Physician "costs" in providing behavioral health in primary care. Clin Pediatr (Phila). 2011; 50(5):447-55. DOI: 10.1177/0009922810390676. View

Haas M, DelBello M, Pandina G, Kushner S, Van Hove I, Augustyns I . Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009; 11(7):687-700. DOI: 10.1111/j.1399-5618.2009.00750.x. View

Morrato E, Nicol G, Maahs D, Druss B, Hartung D, Valuck R . Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010; 164(4):344-51. DOI: 10.1001/archpediatrics.2010.48. View

Findling R, Nyilas M, Forbes R, McQuade R, Jin N, Iwamoto T . Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(10):1441-51. DOI: 10.4088/JCP.09m05164yel. View

Shore J, Brooks E, Savin D, Orton H, Grigsby J, Manson S . Acceptability of telepsychiatry in American Indians. Telemed J E Health. 2008; 14(5):461-6. PMC: 2998941. DOI: 10.1089/tmj.2007.0077. View

Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M . Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005; 58(7):589-94. DOI: 10.1016/j.biopsych.2005.03.019. View

10.

De Hert M, Dobbelaere M, Sheridan E, Cohen D, Correll C . Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011; 26(3):144-58. DOI: 10.1016/j.eurpsy.2010.09.011. View

11.

Zito J, Derivan A, Kratochvil C, Safer D, Fegert J, Greenhill L . Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health. 2008; 2(1):24. PMC: 2566553. DOI: 10.1186/1753-2000-2-24. View

12.

DelBello M, Schwiers M, Lee Rosenberg H, Strakowski S . A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002; 41(10):1216-23. DOI: 10.1097/00004583-200210000-00011. View

13.

Thomas C, Holzer 3rd C . The continuing shortage of child and adolescent psychiatrists. J Am Acad Child Adolesc Psychiatry. 2006; 45(9):1023-1031. DOI: 10.1097/01.chi.0000225353.16831.5d. View

14.

DelBello M, Chang K, Welge J, Adler C, Rana M, Howe M . A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009; 11(5):483-93. DOI: 10.1111/j.1399-5618.2009.00728.x. View

15.

Zito J, Safer D, de Jong-van den Berg L, Janhsen K, Fegert J, Gardner J . A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008; 2(1):26. PMC: 2569908. DOI: 10.1186/1753-2000-2-26. View

16.

Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R . Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007; 164(10):1547-56. DOI: 10.1176/appi.ajp.2007.06111932. View

17.

McCracken J, McGough J, Shah B, Cronin P, Hong D, Aman M . Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002; 347(5):314-21. DOI: 10.1056/NEJMoa013171. View

18.

Larson K, Russ S, Kahn R, Halfon N . Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics. 2011; 127(3):462-70. PMC: 3065146. DOI: 10.1542/peds.2010-0165. View

19.

Olfson M, Crystal S, Huang C, Gerhard T . Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010; 49(1):13-23. DOI: 10.1097/00004583-201001000-00005. View

20.

Egger H . A perilous disconnect: antipsychotic drug use in very young children. J Am Acad Child Adolesc Psychiatry. 2010; 49(1):3-6. View